Repligen Corporation (NASDAQ:RGEN) ("Repligen"), today announced that it entered into privat

WALTHAM, Mass., Oct. 30, 2026 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) (“Repligen”), t

We remain encouraged by the operational performance of the Micro cap companies held in portfolios. T

RBC Capital analyst Dan Leonard maintains Repligen (NASDAQ:RGEN) with a Outperform and raises the

Repligen Corporation (RGEN) Q3 2026 Earnings Call Transcript

Repligen NASDAQ: RGEN reported record third-quarter 2026 revenue of $209 million, surpassing its pri

The Conestoga Small Cap Composite returned -11.22% net of fees in 3Q26, trailing the -9.39% return f

Repligen (RGEN) came out with quarterly earnings of $0.53 per share, beating the Zacks Consensus Est

Repligen (NASDAQ:RGEN) reported third-quarter financial results on Tuesday. The transcript from the

Repligen (NASDAQ:RGEN) raises FY2026 Adj EPS guidance from $2.03-$2.09 to $2.05-$2.09 vs $2.06 analy

Third quarter revenue of $209 million, a year-over-year increase of 11% as reported and 12.5% organi

TMO's organic growth of 5% exceeded consensus by 200 basis points, and management raised full-year o

Canaccord Genuity analyst Kyle Mikson maintains Repligen (NASDAQ:RGEN) with a Hold and raises the

Krilogy Financial LLC lowered its position in shares of Repligen Corporation (NASDAQ: RGEN) by 31.8%

Repligen demonstrates 13% organic growth despite Filtration headwinds, with strong momentum in the P

WALTHAM, Mass., Oct. 13, 2026 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), today announce

Barclays analyst Luke Sergott maintains Repligen (NASDAQ:RGEN) with a Overweight and raises the p

On October 06, 2026, Repligen Corp (RGEN) shares experienced a notable decline of 7.7%, bringing the

WALTHAM, Mass., Oct. 06, 2026 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ: RGEN, “Repligen”, or

On October 05, 2026, Repligen Corp (RGEN) shares rose 4.3%, bringing the current price to $189.50. T

BioLife Solutions NASDAQ: BLFS stockholders approved the company's merger agreement with Repligen Co

Repligen Corporation (NASDAQ: RGEN - Get Free Report) reached a new 52-week high on Wednesday. The s

This whale alert can help traders discover the next big trading opportunities. Whales are entities w

Tidal Investments LLC increased its stake in shares of Repligen Corporation (NASDAQ: RGEN) by 75.2%

NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr.,

Repligen Corporation (RGEN) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript

UBS analyst Dan Leonard maintains Repligen (NASDAQ:RGEN) with a Buy and raises the price target f

Repligen (RGEN) reported earnings 30 days ago. What's next for the stock?

Wells Fargo analyst Evan Stampler maintains Repligen (NASDAQ:RGEN) with a Overweight and raises t

JP Morgan analyst Casey Woodring maintains Repligen (NASDAQ:RGEN) with a Overweight and raises th

A deepening chip rout drags the Nasdaq while Coca-Cola and Sherwin-Williams beats power the Dow; oil

Gainers OPKO Health (NASDAQ:OPK) shares increased by 34.7% to $1.67 during Tuesday's regular se

U.S. stocks mixed, Dow Jones up 300 points. Shares of Sherwin-Williams rose 7.8% after reporting bet

Repligen (NASDAQ:RGEN) reported quarterly earnings of $0.54 per share which beat the analyst consens

Repligen (NASDAQ:RGEN) raises FY2026 Adj EPS guidance from $1.97-$2.05 to $2.03-$2.09 vs $2.00 analy

Repligen to acquire BioLife Solutions for $1.5B to boost cell therapy bioprocessing capabilities and

BioLife stockholders will receive $11.25 per share in cash and 0.1442 shares of Repligen common stoc

Semiconductors led a broad rebound Tuesday as Micron, Western Digital and Sandisk surged. Nasdaq 100

Benchmark analyst Robert Wasserman upgrades Repligen (NASDAQ:RGEN) from Hold to Buy and announces

Evercore ISI Group analyst Daniel Markowitz maintains Repligen (NASDAQ:RGEN) with a Outperform an

HSBC analyst Sidharth Sahoo maintains Repligen (NASDAQ:RGEN) with a Buy and lowers the price targ

Wolfe Research analyst Mike Polark assumes Repligen (NASDAQ:RGEN) with a Outperform rating and an

RBC Capital analyst Dan Leonard reinstates Repligen (NASDAQ:RGEN) with a Outperform and announces

JP Morgan analyst Casey Woodring maintains Repligen (NASDAQ:RGEN) with a Overweight and lowers th

Barclays analyst Luke Sergott maintains Repligen (NASDAQ:RGEN) with a Overweight and raises the p

CURRENT GUIDANCE (at May 5, 2026) FY 2026Adjusted (non-GAAP)Total Reported Revenue$803M - $833MRepor

FINANCIAL GUIDANCE FOR FULL YEAR 2026All adjusted figures are non-GAAPOur financial guidance for the

Repligen (NASDAQ:RGEN) reported quarterly earnings of $0.48 per share which beat the analyst consens

Canaccord Genuity analyst Kyle Mikson maintains Repligen (NASDAQ:RGEN) with a Hold and lowers the